

UKINETS bitesize guidance Management of Refractory Carcinoid Syndrome

Carcinoid syndrome is characterized by cutaneous flushing, gut hypermobility with diarrhoea and bronchospasm. Refractory carcinoid syndrome occurs when symptoms are no longer controlled by standard doses of somatostatin analogues (SSAs) (Octreotide LAR 30mg i.m. or Lanreotide autogel 120mg s.c. every 28 days).

Evaluate for tachyphylaxis and absorption issues such as fibrosis at injection site

Control of symptoms

Tumour control

High tumour burden in liver

Yes

No

Dose escalation of SSA

Increase frequency of long acting SSA to every 3 weeks or 2 weeks (1,2)
Continuous subcutaneous infusion of octreotide
Short acting octreotide s.c. can be used in addition for intermittently increased symptoms
Could consider antihistamines (cyproheptadine or chlorphenamine) +/- oral steroids (i.v. if carcinoid crisis)

Telotristat ethyl 250mg t.i.d. An oral tryptophan hydroxylase inhibitor. Approved for treatment of diarrhoea associated with CS in combination with SSA in patients insufficiently controlled by SSA. Not for routine commissioning in the NHS (7,8) depending on local access

Liver-directed therapies and tumour debulking to reduce the volume of tumour producing hormones (9,10)

Embolisation, resection, RFA, Liver transplantation (in very selected cases, see UKINETS bitesize guidance)*#
following MDT discussion
*Patients with carcinoid syndrome are at risk for developing carcinoid crisis during surgery or other types of intervention (See perioperative management of patients with neuroendocrine tumours, UKINETS bitesize guidance).
#Carcinoid heart disease must be managed prior to surgery

SSA should be continued throughout treatment lines

Dose escalation of SSA

Peptide receptor radionuclide therapy (3)*

Everolimus and SSA (off label) (4)

Interferon alpha (3-5 million IU sc three times weekly) in combination with SSA
Associated with significant toxicity (5)

Pasireotide LAR may be considered off label in very select patients when other treatments fail or are not feasible (6)

UKINETS bitesize guidance

Management of Refractory Carcinoid Syndrome

References

1. Toumpanakis: Antiproliferative Effect of Above-Label Doses of Somatostatin Analogs for the Management of Gastroenteropancreatic Neuroendocrine Tumors. *Neuroendocrinology* (2021) 111 (7): 650–659.
2. Broder: Gastrointestinal neuroendocrine tumors treated with high dose octreotide-LAR: a systematic literature review. *World J Gastroenterol.* 2015; 21: 1945-1955
3. Strosberg: Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors. *N Engl J Med.* 2017 Jan 12;376(2):125-135
4. Pavel: Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. *Lancet* 2011 Dec 10;378(9808):2005-2012
5. Mirvis: Role of Interferon-alpha in Patients with Neuroendocrine Tumors: A Retrospective Study. *Anticancer Research* November 2014, 34 (11) 6601-6607;
6. Wolin E.M: Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues. *Drug Des Devel Ther.* 2015; 9: 5075-5086
7. Pavel: Telotristat ethyl in carcinoid syndrome: safety and efficacy in the TELECAST phase 3 trial. *Endocr Relat Cancer.* 2018; 25: 309-322
8. Kulke: Telotristat ethyl, a tryptophan hydroxylase inhibitor for the treatment of carcinoid syndrome. *J Clin Oncol.* 2017; 35: 14-23
9. ENETS Consensus guidelines. *Neuroendocrinology* 2016;103:172–185
10. ESMO Clinical practice guidelines. *Annals of Oncology.* Volume 31, P844-860, July 2020.

Authors: Charlotte Fribbens